Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Reproducing human and cross-species drug toxicities using a Liver-Chip.

Jang KJ, Otieno MA, Ronxhi J, Lim HK, Ewart L, Kodella KR, Petropolis DB, Kulkarni G, Rubins JE, Conegliano D, Nawroth J, Simic D, Lam W, Singer M, Barale E, Singh B, Sonee M, Streeter AJ, Manthey C, Jones B, Srivastava A, Andersson LC, Williams D, Park H, Barrile R, Sliz J, Herland A, Haney S, Karalis K, Ingber DE, Hamilton GA.

Sci Transl Med. 2019 Nov 6;11(517). pii: eaax5516. doi: 10.1126/scitranslmed.aax5516.

PMID:
31694927
2.

Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective.

Ainslie GR, Davis M, Ewart L, Lieberman LA, Rowlands DJ, Thorley AJ, Yoder G, Ryan AM.

Lab Chip. 2019 Sep 27;19(19):3152-3161. doi: 10.1039/c9lc00492k.

PMID:
31469131
3.

On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships.

McAleer CW, Pointon A, Long CJ, Brighton RL, Wilkin BD, Bridges LR, Narasimhan Sriram N, Fabre K, McDougall R, Muse VP, Mettetal JT, Srivastava A, Williams D, Schnepper MT, Roles JL, Shuler ML, Hickman JJ, Ewart L.

Sci Rep. 2019 Jul 3;9(1):9619. doi: 10.1038/s41598-019-45656-4.

4.

Integrated in vitro models for hepatic safety and metabolism: evaluation of a human Liver-Chip and liver spheroid.

Foster AJ, Chouhan B, Regan SL, Rollison H, Amberntsson S, Andersson LC, Srivastava A, Darnell M, Cairns J, Lazic SE, Jang KJ, Petropolis DB, Kodella K, Rubins JE, Williams D, Hamilton GA, Ewart L, Morgan P.

Arch Toxicol. 2019 Apr;93(4):1021-1037. doi: 10.1007/s00204-019-02427-4. Epub 2019 Mar 26.

PMID:
30915487
5.

Introducing an automated high content confocal imaging approach for Organs-on-Chips.

Peel S, Corrigan AM, Ehrhardt B, Jang KJ, Caetano-Pinto P, Boeckeler M, Rubins JE, Kodella K, Petropolis DB, Ronxhi J, Kulkarni G, Foster AJ, Williams D, Hamilton GA, Ewart L.

Lab Chip. 2019 Jan 29;19(3):410-421. doi: 10.1039/c8lc00829a.

PMID:
30663729
6.

Optimizing drug discovery by Investigative Toxicology: Current and future trends.

Beilmann M, Boonen H, Czich A, Dear G, Hewitt P, Mow T, Newham P, Oinonen T, Pognan F, Roth A, Valentin JP, Van Goethem F, Weaver RJ, Birk B, Boyer S, Caloni F, Chen AE, Corvi R, Cronin MTD, Daneshian M, Ewart LC, Fitzgerald RE, Hamilton GA, Hartung T, Kangas JD, Kramer NI, Leist M, Marx U, Polak S, Rovida C, Testai E, Van der Water B, Vulto P, Steger-Hartmann T.

ALTEX. 2019;36(2):289-313. doi: 10.14573/altex.1808181. Epub 2018 Dec 20.

7.

Advancing nonclinical innovation and safety in pharmaceutical testing.

Baker EJ, Beck NA, Berg EL, Clayton-Jeter HD, Chandrasekera PC, Curley JL, Donzanti BA, Ewart LC, Gunther JM, Kenna JG, LeCluyse EL, Liebman MN, Pugh CL, Watkins PB, Sullivan KM.

Drug Discov Today. 2019 Feb;24(2):624-628. doi: 10.1016/j.drudis.2018.11.011. Epub 2018 Nov 20. Review.

8.

Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting.

Fabre KM, Delsing L, Hicks R, Colclough N, Crowther DC, Ewart L.

Adv Drug Deliv Rev. 2019 Feb 1;140:129-135. doi: 10.1016/j.addr.2018.09.009. Epub 2018 Sep 22. Review.

PMID:
30253201
9.

Publisher Correction: Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model.

Bauer S, Wennberg Huldt C, Kanebratt KP, Durieux I, Gunne D, Andersson S, Ewart L, Haynes WG, Maschmeyer I, Winter A, Ämmälä C, Marx U, Andersson TB.

Sci Rep. 2018 Jan 23;8(1):1672. doi: 10.1038/s41598-018-20340-1.

10.

The impact of simulation based education on nursing confidence, knowledge and patient outcomes on general medicine units.

Crowe S, Ewart L, Derman S.

Nurse Educ Pract. 2018 Mar;29:70-75. doi: 10.1016/j.nepr.2017.11.017. Epub 2017 Nov 26.

PMID:
29190590
11.

Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model.

Bauer S, Wennberg Huldt C, Kanebratt KP, Durieux I, Gunne D, Andersson S, Ewart L, Haynes WG, Maschmeyer I, Winter A, Ämmälä C, Marx U, Andersson TB.

Sci Rep. 2017 Nov 6;7(1):14620. doi: 10.1038/s41598-017-14815-w. Erratum in: Sci Rep. 2018 Jan 23;8(1):1672.

12.

Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery.

Ewart L, Dehne EM, Fabre K, Gibbs S, Hickman J, Hornberg E, Ingelman-Sundberg M, Jang KJ, Jones DR, Lauschke VM, Marx U, Mettetal JT, Pointon A, Williams D, Zimmermann WH, Newham P.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:65-82. doi: 10.1146/annurev-pharmtox-010617-052722. Epub 2017 Oct 13. Review.

PMID:
29029591
13.

BMP7-induced-Pten inhibits Akt and prevents renal fibrosis.

Higgins DF, Ewart LM, Masterson E, Tennant S, Grebnev G, Prunotto M, Pomposiello S, Conde-Knape K, Martin FM, Godson C.

Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3095-3104. doi: 10.1016/j.bbadis.2017.09.011. Epub 2017 Sep 18.

14.

Rising to the challenge: applying biofabrication approaches for better drug and chemical product development.

Holmes AM, Charlton A, Derby B, Ewart L, Scott A, Shu W.

Biofabrication. 2017 Jul 19;9(3):033001. doi: 10.1088/1758-5090/aa7bbd. Review.

15.

Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective.

Ewart L, Fabre K, Chakilam A, Dragan Y, Duignan DB, Eswaraka J, Gan J, Guzzie-Peck P, Otieno M, Jeong CG, Keller DA, de Morais SM, Phillips JA, Proctor W, Sura R, Van Vleet T, Watson D, Will Y, Tagle D, Berridge B.

Exp Biol Med (Maywood). 2017 Oct;242(16):1579-1585. doi: 10.1177/1535370217715441. Epub 2017 Jun 16.

16.

Profibrotic IHG-1 complexes with renal disease associated HSPA5 and TRAP1 in mitochondria.

Bhreathnach U, Griffin B, Brennan E, Ewart L, Higgins D, Murphy M.

Biochim Biophys Acta Mol Basis Dis. 2017 Apr;1863(4):896-906. doi: 10.1016/j.bbadis.2017.01.015. Epub 2017 Jan 20.

17.

Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials.

Mead AN, Amouzadeh HR, Chapman K, Ewart L, Giarola A, Jackson SJ, Jarvis P, Jordaan P, Redfern W, Traebert M, Valentin JP, Vargas HM.

Regul Toxicol Pharmacol. 2016 Oct;80:348-57. doi: 10.1016/j.yrtph.2016.05.002. Epub 2016 May 4.

18.

The value of integrating pre-clinical data to predict nausea and vomiting risk in humans as illustrated by AZD3514, a novel androgen receptor modulator.

Grant C, Ewart L, Muthas D, Deavall D, Smith SA, Clack G, Newham P.

Toxicol Appl Pharmacol. 2016 Apr 1;296:10-8. doi: 10.1016/j.taap.2016.02.007. Epub 2016 Feb 11.

PMID:
26876616
19.

A peripherally restricted P2Y12 receptor antagonist altered rat tumor incidences with no human relevance: Mode of action consistent with dopamine agonism.

Brott DA, Andersson HAS, Stewart J, Ewart L, Christoph G, Harleman J, Armstrong D, Kinter LB.

Toxicol Rep. 2014 Nov 20;1:1202-1212. doi: 10.1016/j.toxrep.2014.11.010. eCollection 2014.

20.

The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.

Ewart L, Aylott M, Deurinck M, Engwall M, Gallacher DJ, Geys H, Jarvis P, Ju H, Leishman D, Leong L, McMahon N, Mead A, Milliken P, Suter W, Teisman A, Van Ammel K, Vargas HM, Wallis R, Valentin JP.

Toxicol Sci. 2014 Dec;142(2):427-35. doi: 10.1093/toxsci/kfu198. Epub 2014 Sep 21.

PMID:
25246669
21.

Translational potential of a mouse in vitro bioassay in predicting gastrointestinal adverse drug reactions in Phase I clinical trials.

Keating C, Ewart L, Grundy L, Valentin JP, Grundy D.

Neurogastroenterol Motil. 2014 Jul;26(7):980-9. doi: 10.1111/nmo.12349. Epub 2014 May 11.

22.

Patient- and family-centred care on an acute adult cardiac ward.

Ewart L, Moore J, Gibbs C, Crozier K.

Br J Nurs. 2014 Feb 27-Mar 12;23(4):213-8.

PMID:
24809150
23.

Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1.

Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ.

J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):209-19. doi: 10.1177/1074248413511693. Epub 2014 Jan 10.

PMID:
24414167
24.

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions.

Ewart L, Milne A, Adkins D, Benjamin A, Bialecki R, Chen Y, Ericsson AC, Gardner S, Grant C, Lengel D, Lindgren S, Lowing S, Marks L, Moors J, Oldman K, Pietras M, Prior H, Punton J, Redfern WS, Salmond R, Skinner M, Some M, Stanton A, Swedberg M, Finch J, Valentin JP.

J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):30-43. doi: 10.1016/j.vascn.2013.04.008. Epub 2013 May 9.

PMID:
23665080
25.

Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human.

Parkinson J, Visser SA, Jarvis P, Pollard C, Valentin JP, Yates JW, Ewart L.

J Pharmacol Toxicol Methods. 2013 Nov-Dec;68(3):357-66. doi: 10.1016/j.vascn.2013.03.007. Epub 2013 Apr 6.

PMID:
23567074
26.

An evaluation of the non-invasive faecal pellet assessment method as an early drug discovery screen for gastrointestinal liability.

Marks L, Beard E, Cobey D, Moore N, Motyer V, Valentin JP, Ewart L.

J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):123-36. doi: 10.1016/j.vascn.2013.03.006. Epub 2013 Mar 28.

PMID:
23542059
27.

Refinement of the charcoal meal study by reduction of the fasting period.

Prior H, Ewart L, Bright J, Valentin JP.

Altern Lab Anim. 2012 May;40(2):99-107.

PMID:
22762194
28.

The role of the anaesthetised guinea-pig in the preclinical cardiac safety evaluation of drug candidate compounds.

Marks L, Borland S, Philp K, Ewart L, Lainée P, Skinner M, Kirk S, Valentin JP.

Toxicol Appl Pharmacol. 2012 Sep 1;263(2):171-83. doi: 10.1016/j.taap.2012.06.007. Epub 2012 Jun 17.

PMID:
22714037
29.

How do the top 12 pharmaceutical companies operate safety pharmacology?

Ewart L, Gallacher DJ, Gintant G, Guillon JM, Leishman D, Levesque P, McMahon N, Mylecraine L, Sanders M, Suter W, Wallis R, Valentin JP.

J Pharmacol Toxicol Methods. 2012 Sep;66(2):66-70. doi: 10.1016/j.vascn.2012.03.004. Epub 2012 Apr 1.

PMID:
22510338
30.

Application of data mining and visualization techniques for the prediction of drug-induced nausea in man.

Parkinson J, Muthas D, Clark M, Boyer S, Valentin JP, Ewart L.

Toxicol Sci. 2012 Mar;126(1):275-84. doi: 10.1093/toxsci/kfr334. Epub 2011 Dec 9.

PMID:
22157355
31.

Are you aware of awareness?

Ewart L.

J Perioper Pract. 2011 Mar;21(3):93-6.

PMID:
21488460
32.
33.

The validation of an in vitro colonic motility assay as a biomarker for gastrointestinal adverse drug reactions.

Keating C, Martinez V, Ewart L, Gibbons S, Grundy L, Valentin JP, Grundy D.

Toxicol Appl Pharmacol. 2010 Jun 15;245(3):299-309. doi: 10.1016/j.taap.2010.03.014. Epub 2010 Mar 27.

PMID:
20350559
34.

Pharmacological validation of a telemetric model for the measurement of bronchoconstriction in conscious rats.

Ewart LC, Haley M, Bickerton S, Bright J, Elliott K, McCarthy A, Williams L, Ricketts SA, Holland T, Valentin JP.

J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):219-29. doi: 10.1016/j.vascn.2010.02.008. Epub 2010 Feb 26.

PMID:
20219687
35.

A framework to assess the translation of safety pharmacology data to humans.

Valentin JP, Bialecki R, Ewart L, Hammond T, Leishmann D, Lindgren S, Martinez V, Pollard C, Redfern W, Wallis R.

J Pharmacol Toxicol Methods. 2009 Sep-Oct;60(2):152-8. doi: 10.1016/j.vascn.2009.05.011. Epub 2009 Jul 17.

PMID:
19616110
36.

Mechanical and electromechanical properties of PMNT single crystals for naval sonar transducers.

Ewart LM, McLaughlin EA, Robinson HC, Stace JJ, Amin A.

IEEE Trans Ultrason Ferroelectr Freq Control. 2007 Dec;54(12):2469-73. doi: 10.1109/TUFFC.2007.561.

PMID:
18276539
37.
38.

Mechanical and thermal transitions in morphotropic PZN-pT and PMN-PT single crystals and their implication for sound projectors.

Amin A, McLaughlin E, Robinson H, Ewart L.

IEEE Trans Ultrason Ferroelectr Freq Control. 2007 Jun;54(6):1090-5.

PMID:
17571807
39.

Putting children first.

Ewart L, Barnes K.

Nurs Manag (Harrow). 1999 May;6(2):27-30. No abstract available.

PMID:
10478080
40.

Make your mark.

Ewart L.

Paediatr Nurs. 1998 Apr;10(3):8-9. No abstract available.

PMID:
9687769

Supplemental Content

Support Center